Phase I/II studies of BAY 43-9006 (sorafenib) in combination with OSI-774 (erlotinib), R115777 (tipifarnib) or CCI-779 (temsirolimus) in patients with recurrent glioblastoma multiforme or gliosarcoma.

Trial Profile

Phase I/II studies of BAY 43-9006 (sorafenib) in combination with OSI-774 (erlotinib), R115777 (tipifarnib) or CCI-779 (temsirolimus) in patients with recurrent glioblastoma multiforme or gliosarcoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Erlotinib (Primary) ; Sorafenib (Primary) ; Temsirolimus (Primary) ; Tipifarnib (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Jun 2012 Actual patient number is 90 as reported by ClinicalTrials.gov.
    • 07 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top